Loading…
Immuron Limited is projected to rise to $1.28 by 2027, a +21% move from its current price of $1.06. IMRN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.02 | $1.06 | $1.10 | +0.14% |
| Aug 6 | $1.01 | $1.06 | $1.12 | +0.27% |
| Aug 7 | $0.9942 | $1.06 | $1.14 | +0.41% |
| Aug 8 | $0.9851 | $1.07 | $1.15 | +0.54% |
| Aug 9 | $0.9773 | $1.07 | $1.17 | +0.68% |
| Aug 10 | $0.9705 | $1.07 | $1.18 | +0.81% |
| Aug 11 | $0.9643 | $1.07 | $1.19 | +0.95% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.9643 | $1.07 | $1.19 | +0.95% |
| Week 2 | $0.9324 | $1.08 | $1.25 | +1.91% |
| Week 3 | $0.9106 | $1.09 | $1.31 | +2.88% |
| Week 4 | $0.894 | $1.10 | $1.36 | +3.85% |
| Week 5 | $0.8806 | $1.11 | $1.40 | +4.84% |
| Week 6 | $0.8694 | $1.12 | $1.45 | +5.83% |
| Week 7 | $0.8599 | $1.13 | $1.49 | +6.84% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Immuron Limited is a biopharmaceutical company that researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products, and offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders, as well as Protectyn, an immune supplement to help maintain a healthy digestive function and liver.
It also develops Travelan (IMM-124E), which is in Phase II clinical trial, to reduce the risk of contracting travelers' diarrhea; and IMM-529, which is in Phase II clinical trial, for treating patients suffering from recurring clostridium difficile infection. In additon, the company develops IMM-986, that is in pre-clinical stage. Further, it offers technology platform.
The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products. The company was formerly known as Anadis Limited and changed its name to Immuron Limited in December 2008. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
Immuron Limited (IMRN) is a healthcare company with a current price of $1.11 and a market cap of $8.96M. It ranks 4894 in market capitalization among listed assets. The longer-term price outlook shows a path of growth in the coming years, with 2026 average price around $1.11 and substantial upside possible by 2050, including a 2050 average of $12.01 and a 2050 max of $27.30.
The 30-day technical backdrop sets the stage for near-term movement as investors size up the stock’s risk/return profile over a single-month horizon.
A major floor 28.3% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 25.5% above — a clean break opens room to run.
A major ceiling 36.8% above — clearing it would confirm fresh momentum.
Key IMRN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IMRN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.09 | Sell | $1.10 | Sell |
| MA 10 | $1.12 | Sell | $1.12 | Sell |
| MA 20 | $1.17 | Sell | $1.14 | Sell |
| MA 50 | $1.16 | Sell | $1.11 | Sell |
| MA 100 | $0.997 | Buy | $1.08 | Sell |
| MA 200 | $1.12 | Sell | $1.18 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.83 | Neutral |
| Stoch RSI (14) | 17.42 | Buy |
| CCI (20) | -84.80 | Neutral |
| Williams %R (14) | -83.33 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -8.40 | Sell |
| Bollinger %B (20,2) | 0.22 | Neutral |
| Stochastic %K (14) | 16.67 | Buy |
| TRIX (15) | -0.02 | Sell |
| Awesome (5,34) | -0.05 | Sell |
| Ultimate (7,14,28) | 41.76 | Neutral |
| Momentum (10) | -0.12 | Sell |
| Aroon Osc (25) | -52.00 | Sell |
| Hull MA (9) | 1.08 | Sell |
| ADX (14) | 9.27 | Neutral |
| ATR (14) | 0.04 | Info |
The 30-day picture is NEUTRAL.
RSI(14) sits at 50, and both the 50-day and 200-day simple moving averages align at $1.15. Near-term support sits at $1.06, with a resistance at $1.33.
The latest 30-day range spans from $0.8296 to $1.49.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.70 | $1.06 | $1.52 | 0% | Neutral | |
| $0.981 | $1.28 | $1.79 | +21% | Bullish | |
| $1.18 | $1.61 | $2.36 | +52% | Bullish | |
| $1.53 | $2.16 | $3.30 | +104% | Bullish | |
| $1.57 | $2.28 | $3.61 | +116% | Bullish | |
| $1.53 | $2.30 | $3.74 | +117% | Bullish | |
| $1.53 | $2.35 | $3.93 | +122% | Bullish | |
| $1.57 | $2.49 | $4.25 | +135% | Bullish | |
| $1.80 | $2.93 | $5.10 | +176% | Bullish | |
| $2.09 | $3.47 | $6.17 | +228% | Bullish | |
| $2.31 | $4.31 | $8.27 | +306% | Bullish | |
| $5.31 | $11.81 | $25.39 | +10.1x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.70 | $1.06 | $1.31 | +0.00% |
| September 2026 | $0.9718 | $1.16 | $1.44 | +9.78% |
| October 2026 | $0.9912 | $1.20 | $1.51 | +3.02% |
| November 2026 | $0.954 | $1.16 | $1.48 | -2.95% |
| December 2026 | $0.9596 | $1.18 | $1.52 | +1.34% |
Click any year to see its month-by-month IMRN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, IMRN could reach as high as $1.52, with a base case around $1.06 and support toward $0.70 — roughly 0% from $1.06. A consolidation phase looks the most probable path here.
Expect IMRN to range from $0.981 to $1.79 through 2027. The $1.28 average target implies a +21% move from current prices. That is up +21% on the projected 2026 average. Momentum favours further upside here.
The IMRN price prediction for 2028 points to an average of $1.61 (low $1.18, high $2.36) — a potential gain of +52% on today's $1.06. Buyers look set to stay in control over this stretch.
In 2029, IMRN is projected to trade between $1.53 and $3.30, averaging $2.16 — a potential gain of +104% from today's $1.06. That is up +34% on the projected 2028 average. Momentum favours further upside here.
Immuron Limited's 2030 outlook centres on $2.28, within a $1.57 to $3.61 range. That is up +6% on the projected 2029 average. That marks a +116% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, IMRN could reach as high as $3.74, with a base case around $2.30 and support toward $1.53 — roughly +117% from $1.06. Momentum favours further upside here.
Expect IMRN to range from $1.53 to $3.93 through 2032. The $2.35 average target implies a +122% move from current prices. That is up +2% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The IMRN price prediction for 2033 points to an average of $2.49 (low $1.57, high $4.25) — a potential gain of +135% on today's $1.06. Momentum favours further upside here.
In 2034, IMRN is projected to trade between $1.80 and $5.10, averaging $2.93 — a potential gain of +176% from today's $1.06. That is up +18% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Immuron Limited's 2035 outlook centres on $3.47, within a $2.09 to $6.17 range. That is up +19% on the projected 2034 average. That marks a +228% change versus current levels. Momentum favours further upside here.
By 2040, IMRN could reach as high as $8.27, with a base case around $4.31 and support toward $2.31 — roughly +306% from $1.06. Buyers look set to stay in control over this stretch.
Expect IMRN to range from $5.31 to $25.39 through 2050. The $11.81 average target implies a +10.1x move from current prices. That is up +174% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in IMRN today (≈ 943.396226 IMRN) could be worth
$11,137.86
+$10,137.86 (+1014%) by 2050 · US Dollar
Based on the average projected IMRN price of $11.81 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IMRNwould be worth at today's price.
$1,000 invested in IMRN on Jul 31, 2025 (≈ 617.283949 IMRN) would be worth
$654.32
-$345.68 (-34.6%) today · 0.65× · US Dollar
Based on a IMRN entry price of $1.62 vs. today's $1.06.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.11 | $954.95 | -4.5% |
| 1 month ago | $1.09 | $972.48 | -2.8% |
| 3 months ago | $0.792 | $1,338.38 | +33.8% |
| 6 months ago | $0.901 | $1,176.47 | +17.6% |
| 1 year ago | $1.62 | $654.32 | -34.6% |
| All time (5.0y) ago | $4.85 | $218.56 | -78.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IMRN forecast.
Our base-case forecast reaches $2.10 around 2029.
Implied market cap at $2.10: $16.95M
The multi-year forecast skews bullish from the latter part of the decade onward. The 2026 forecast places the average price at $1.11 with 0% ROI and NEUTRAL sentiment.
The path toward 2030 heads higher, with 2027 average $1.32 and ROI 18.5%, 2028 average $1.66 and ROI 49.5%, 2029 average $2.33 and ROI 109.9%, and 2030 average $2.37 with ROI 113.3% and a BULLISH tilt.
By 2034, the average advances to $2.91 with a max of $5.28 and ROI 162.2%; 2035 shows $3.59 average and ROI 223.6%. The 2040 snapshot yields an average of $4.23 and a max of $8.53, with ROI 281.2%, while the 2050 horizon projects an average of $12.01 and a max of $27.30, with ROI 982.3% and a BULLISH sentiment. These figures reflect potential upside against the current level but remain estimates, not guarantees, and depend on a range of factors.
Tap a question to reveal the answer.
Avg $2.37; min $1.57; max $3.87; ROI 113.3%; sentiment BULLISH.
Forecasts show a path from 2026 avg $1.11 to 2050 avg $12.01 with bullish sentiment from 2028 onward; ROIs include 18.5% in 2027, 49.5% in 2028, 109.9% in 2029, 113.3% in 2030, and 982.3% in 2050.
2034 max $5.28; 2034 avg $2.91; 2034 min $1.70.
Current price $1.11; market cap $8.96M.
30-day range low $0.8296; high $1.49.
Immuron Limited Community Discussion
0Share your Immuron Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.